



PRESS RELEASE

## **Moberg Pharma's Interim report for July 2019 - September 2020 to be published on November 10 - Invitation to teleconference**

**STOCKHOLM, November 3<sup>rd</sup>, 2020 - On November 10<sup>th</sup>, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - September 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.**

The teleconference will be hosted by Moberg Pharmas's CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English.

Date: November 10<sup>th</sup>, 2020  
Time: 3:00 pm (CET)

To participate in the conference, please dial in on any number below before the start of the call:

SE: +46 8 566 427 07  
US: +1 833 249 84 04

The quarterly report and other information material will be made public on:  
<http://www.mobergpharma.com/investors/calendarpresentations>

**For additional information, please contact:**

Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-post: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: [mark.beveridge@mobergpharma.se](mailto:mark.beveridge@mobergpharma.se)

**About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).